Tibet Aim Pharm

Tibet Aim Pharm Dividend Coverage

The Dividend Coverage Ratio of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 5.09. In the previous year, Dividend Coverage Ratio was 9.30 — a change of -45.28% (lower).

Dividend Coverage

5.09

YoY

-45.28%

Last updated:

Dividend Coverage Ratio of Tibet Aim Pharm is 2025 5.09 . Dividend Coverage Ratio of Tibet Aim Pharm was 2024 9.30 . It decreases by -45.28% lower compared to the previous year.

The Tibet Aim Pharm Dividend Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend Coverage
Date
Dividend Coverage
Jan 1, 2018
1.99 CNY
Jan 1, 2019
7.72 CNY
Jan 1, 2020
5.79 CNY
Jan 1, 2021
2.64 CNY
Jan 1, 2022
2.35 CNY
Jan 1, 2023
0.71 CNY
Jan 1, 2024
9.30 CNY
Jan 1, 2025
5.09 CNY
The Tibet Aim Pharm Dividend Coverage history
YEARDividend CoverageYoY
5.09-45.28%
9.30+1,218.22%
0.71-69.92%
2.35-11.11%
2.64-54.44%
5.79-24.99%
7.72+287.66%
1.99-61.01%
5.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

Dividend Coverage Ratio of Tibet Aim Pharm is 5.09 in 2025.

Dividend Coverage Ratio of Tibet Aim Pharm changed from 9.30 to 5.09, representing a -45.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Tibet Aim Pharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm